Zobrazeno 1 - 10
of 104
pro vyhledávání: ''
Autor:
Nicholas J. Short, Sangeetha Venugopal, Wei Qiao, Tapan M. Kadia, Farhad Ravandi, Walid Macaron, Courtney D. Dinardo, Naval Daver, Marina Konopleva, Gautam Borthakur, Elizabeth J. Shpall, Uday Popat, Richard E. Champlin, Rohtesh Mehta, Gheath Al-Atrash, Betul Oran, Elias Jabbour, Guillermo Garcia-Manero, Ghayas C. Issa, Guillermo Montalban-Bravo, Musa Yilmaz, Abhishek Maiti, Hagop Kantarjian
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-10 (2022)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Background Treated secondary acute myeloid leukemia (ts-AML)—i.e., AML arising from a previously treated antecedent hematologic disorder—is associated with very poor outcomes. The optimal frontline treatment regimen for these patients is uncertai
Autor:
Taro Shibuki, Toshihiko Mizuta, Mototsugu Shimokawa, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Masaru Fukahori, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Kenji Mitsugi, Kenta Nio, Yasushi Ide, Norio Ureshino, Tsuyoshi Shirakawa, Taiga Otsuka
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
BMC Cancer
BMC Cancer
Background No reliable nomogram has been developed until date for predicting the survival in patients with unresectable pancreatic cancer undergoing treatment with gemcitabine plus nab–paclitaxel (GnP) or FOLFIRINOX. Methods This analysis was condu
Autor:
Mitsuru Sugimoto, Tadayuki Takagi, Rei Suzuki, Naoki Konno, Hiroyuki Asama, Yuki Sato, Hiroki Irie, Yoshinori Okubo, Jun Nakamura, Mika Takasumi, Minami Hashimoto, Tsunetaka Kato, Ryoichiro Kobashi, Takuto Hikichi, Hiromasa Ohira
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
BMC Cancer
BMC Cancer
Background The prognosis of pancreatic cancer (PC) has been improved by new chemotherapy regimens (combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel (GnP)). Unfortunately, chemother
Autor:
Xiaoyong Huang, Zhiqiang Wu, Wenbo Guo, Zhiyong Liu, Tengfei Li, Xu Bo, Weiguang Yu, Song Chen, Yanqing Wu, Pengfei Wang
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
BMC Cancer
BMC Cancer
Background Not all patients with unresectable hepatocellular carcinoma (uHCC) benefit from treatment with immune checkpoint inhibitors and molecular-targeted agents. The aim of this retrospective study was to assess the efficacy and safety of pembrol
Autor:
Frederic Peyrade, Graham P. Collins, Yihua Lee, Jutta K. Neuenburg, Michael Wang, Robert T. Chen, Geoffrey Chong, Karl Eckert, Constantine S. Tam, Radhakrishnan Ramchandren, Lionel Karlin, Ka Lung Wu, Mark Bishton, Paul Eliadis, Wojciech Jurczak
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-8 (2021)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL). The ongoing phase 3 SYMPATICO study evaluates the safety and efficacy of concurrently administer
Autor:
Liru He, Yijun Zhang, Dong Chen, Yanjun Wang, Yonghong Li, Jun Wang, Hao Zeng, Yanxia Shi, Fangjian Zhou, Zhenyu Yang, Yuchao Ni, Zhiming Wu, Lijuan Jiang, Diwei Zhao
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Cancer
BMC Cancer
BackgroundTo assess the efficacies and potential predictors of a corticosteroid switch in metastatic castration-resistant prostate cancer (mCRPC) patients with biochemical progression on abiraterone acetate plus prednisone (A + P).MethodsPatients wit
Autor:
Yusuke Sano, Hiroyuki Asama, Taito Fukushima, Shun Tezuka, Makoto Ueno, Kuniyuki Kawano, Manabu Morimoto, Shuhei Nagashima, Satoshi Kobayashi
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Cancer
BMC Cancer
Background Malignant gastric outlet obstruction (MGOO) occasionally occurs due to pancreaticobiliary cancer. Endoscopic duodenal stenting (DS) is a common treatment for MGOO. However, it has been reported that DS does not have sufficient patency time
Autor:
Julia Schollbach, Nicolas Schlegel, Ingo Klein, Matthias Kelm, Friedrich Anger, Stefan Löb, Volker Kunzmann, Christoph-Thomas Germer, Armin Wiegering
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Cancer
BMC Cancer
Background A prognostic benefit of additive chemotherapy in patients following resection of metachronous colorectal liver metastases (CRLM) remains controversial. Therefore, the goal of this retrospective study was to investigate the impact of periop
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
BMC Cancer
BMC Cancer
Background Regorafenib has shown promising results as a second-line therapy for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib. Although there have been several data regarding the efficacy of sequential therapy with sorafeni
Autor:
Yunfan Luo, Wei Liu, Ze-Hong Lv, Junzheng Li, Bolong Yu, Juan Lu, Xiaofei Yuan, Yanfei Li, Xiong Liu, Xiaohong Peng, Xinyu Peng, Bijun Liang, Shuting Wu
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
BMC Cancer
BMC Cancer
Background Although the National Comprehensive Cancer Network (NCCN) Guidelines recommend CCRT+AC and IC + CCRT as level 2A evidence for treatment of the locoregionally advanced NPC (II-IVa), IC + CCRT+AC could also be an alternative but it is seldom